Triple Play On How They Differentiate Themselves In The Digital Signage Space at InfoComm 2018

MarketScale recently attended InfoComm 2018 and was lucky enough to catch up with Michael Baez from Triple Play. As Regional Sales Manager, Baez offered insight into the company’s appreciation of the event as well as some key methods Triple Play uses to stay relevant and ahead of the game.

Baez and his team keep coming back to InfoComm because it offers them a chance to showcase their latest technology and the progression of their products. As a software company, Triple Play offers four core products: IPTV, video on-demand, digital signage, and streaming to tablets and mobile devices. A key differentiator for Triple Play is that it hosts all four products on a single platform from a single server.

For Triple Play, it is all about the customer, according to Baez. He explained how its innovation is tied to customer needs. Instead of sitting in a room searching for ideas, the team is in communication with customers and listening to their needs; this information becomes the springboard for product development. With this commitment to clients, word of mouth is a major catalyst for market growth, so they take these relationships seriously. In fact, one of their greatest acquisitions, a contract in 2016 with the Miami Marlins, was the result of a recommendation from a happy customer.

This new partnership is also evidence of the importance of gaining and maintaining trust. The Marlins came in with a lot of faith in the company, and maintained that feeling by treating the customer well.

While sports venues are a large part of its customer base, Triple Play’s verticals focus on a wide range of industries, from corporate to hospitality to health care and military deployments. Baez pointed out that the company’s solutions are nimble enough to stream to any device, keeping them in demand in a diversity of business and entertainment fields.

In closing, Baez stated that Triple Play will keep coming back to InfoComm because they love the fun social aspect but also appreciate the opportunity to meet new clients. He wants his potential customers to know that they can expect a high level of support from his team, and that the pros at Triple Play will take good care of them. He added that their clients “can feel comfortable with their quality software and confident about their decision to move forward with Triple Play.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More